These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9385494)

  • 1. Safety surveillance of esterified estrogens-methyltestosterone (Estratest and Estratest HS) replacement therapy in the United States.
    Phillips E; Bauman C
    Clin Ther; 1997; 19(5):1070-84. PubMed ID: 9385494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estratest and Estratest HS (esterified estrogens and methyltestosterone) therapy: a summary of safety surveillance data, January 1989 to August 2002.
    Phillips EH; Ryan S; Ferrari R; Green C
    Clin Ther; 2003 Dec; 25(12):3027-43. PubMed ID: 14749144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esterified estrogens combined with methyltestosterone improve emotional well-being in postmenopausal women with chest pain and normal coronary angiograms.
    Adamson DL; Webb CM; Collins P
    Menopause; 2001; 8(4):233-8. PubMed ID: 11449079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esterified estrogens combined with methyltestosterone raise intraocular pressure in postmenopausal women.
    Khurana RN; LaBree LD; Scott G; Smith RE; Yiu SC
    Am J Ophthalmol; 2006 Sep; 142(3):494-5. PubMed ID: 16935599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study.
    Liu J; Allgood A; Derogatis LR; Swanson S; O'Mahony M; Nedoss B; Soper H; Zbella E; Prokofieva SV; Zipfel L; Guo CY
    Fertil Steril; 2011 Jan; 95(1):366-8. PubMed ID: 20850731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estratest is not approved by the Food and Drug Administration.
    Suthers K
    Arch Intern Med; 2007 Jan; 167(2):205-6. PubMed ID: 17242325
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause.
    Watts NB; Notelovitz M; Timmons MC; Addison WA; Wiita B; Downey LJ
    Obstet Gynecol; 1995 Apr; 85(4):529-37. PubMed ID: 7898828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women.
    Hickok LR; Toomey C; Speroff L
    Obstet Gynecol; 1993 Dec; 82(6):919-24. PubMed ID: 8233265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women.
    Dobs AS; Nguyen T; Pace C; Roberts CP
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1509-16. PubMed ID: 11932273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
    Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
    Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire.
    Lobo RA; Rosen RC; Yang HM; Block B; Van Der Hoop RG
    Fertil Steril; 2003 Jun; 79(6):1341-52. PubMed ID: 12798881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women.
    Warnock JK; Swanson SG; Borel RW; Zipfel LM; Brennan JJ;
    Menopause; 2005; 12(4):374-84. PubMed ID: 16037752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
    Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks of menopausal androgen supplementation.
    Slayden SM
    Semin Reprod Endocrinol; 1998; 16(2):145-52. PubMed ID: 9711680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
    Voth M; Rosenberg M; Breuer J
    Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women.
    Chiuve SE; Martin LA; Campos H; Sacks FM
    J Clin Endocrinol Metab; 2004 May; 89(5):2207-13. PubMed ID: 15126543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
    Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
    Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of estrogen/androgen regimens.
    Simon JA
    J Reprod Med; 2001 Mar; 46(3 Suppl):281-90. PubMed ID: 11304876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.